While not the focus of this repurposing study, oral GLP-1 receptor agonists are becoming available (e.g. semaglutide) which would be an easier dosing route for future studies [213], while alogliptin, an oral compound inhibiting DPP-4, the enzyme that inactivates GLP-1, thus boosting GLP-1 indirectly, is also trialled in PD [214]. The gene discussed is DPP4; the disease is Parkinson disease.